Pillars of pharmaceutical IP: Regulatory exclusivity regime in China

I. Core protection mechanisms and duration

1. Definition and scope for protection

Data eligible for protection must be "independently obtained," "undisclosed," "submitted for the first marketing authorization application in China," and "complete.” Recognizing that major global regulators routinely mandate the publication of clinical trial summaries on publicly accessible clinical trial registry platforms, the Implementation Measures provide a critical safe harbor: prior partial disclosures of certain general clinical trial information will not jeopardize the data's "undisclosed" status in China, provided the dataset as a whole has not been published in its entirety. This pragmatic acknowledgment of global regulatory realities offers certainty to originators navigating simultaneous multi-jurisdictional filings.

The scope of protection varies significantly based on the drug's degree of innovation:

• Innovative Drugs (Class 1) and Equivalent Scenarios: These enjoy the broadest protection, covering all trial data demonstrating safety, efficacy, and quality control (encompassing pharmaceutical (CMC) data, non-clinical study data, and clinical study data). Equivalent scenarios refer to: (a) original drugs that have been marketed outside China but not yet approved for marketing in China; and (b) drugs whose active ingredients have been marketed outside China but not yet in China, where the indication for which marketing authorization is first sought in China has not been approved in any jurisdiction, whether in China or abroad.
• New Indications for Drugs Already Granted Trial Data Protection: The scope of protection is limited strictly to the new clinical trial data supporting that specific marketing authorization.
• Improved New Drugs and First Generics: Protection is restricted to new data demonstrating obvious clinical advantages, or to necessary clinical trial data supporting approval.

Bioavailability (BA), bioequivalence (BE) data, and immunogenicity data for vaccines are explicitly excluded from the scope of protection.

2. Overview of core protection periods

The Implementation Measures establish differentiated protection periods based on drug registration categories, as summarized below.

By comparison, the European Union provides eight years of data exclusivity (plus two years of market exclusivity) for innovative medicines, while the United States grants five years for new chemical entities and twelve years for biological products. China’s six-year period for innovative drugs and equivalent scenarios thus represents a substantial commitment to regulatory data protection, though one that stays below the terms in other major jurisdictions, reflecting likely an attempt to reach an approach balancing innovation incentives with public health access objectives.

3. Additional rules of particular significance for multinational companies

• Gradient Incentives for New Indications: For original drugs marketed overseas but not in China, where a new indication that has not been approved in any jurisdiction is submitted for the first time in China, an equivalent 6-year protection period will be granted under the innovative drug standard, and the scope of data protection will cover all trial data demonstrating the drug’s safety, efficacy, and quality control, as described above. Subsequent additions of indications for the same product will receive 4-year protection.
• Incentives for Local Manufacturing: The Implementation Measures explicitly encourage foreign companies to transfer the production of imported original drugs marketed in China to domestic manufacturing facilities. Where an imported original drug has already obtained data protection in China, the holder of the overseas original drug, or the holder of the domestically produced drug (with the former's consent), may fully inherit the remaining data protection period of the imported original drug within the original protection period. The NMPA will continue to block marketing applications for generic drugs relying on such protected data.

II. Application procedures, exclusivity, and ex-officio review

• Simultaneous Application: Applicants seeking data protection must submit the request concurrently with their New Drug Application (NDA).
• Regulatory Stay (Non-acceptance and Non-approval): Outside the one-year window prior to expiration of the data protection period, marketing applications relying on protected data will not be accepted. Submissions are permitted within one year before expiration, but China’s Center for Drug Evaluation (CDE) will suspend the review clock upon completing the technical review, and marketing approval will be granted only after the data protection period has fully expired.
• Proactive Ex Officio Review: Where an applicant claims that its data was independently obtained, but the CDE discovers during the review process that the application in fact relies on protected data, the application will not be approved.

III. Critical action window: Rights preservation for transition pipeline products

For drug pipelines already in the regulatory process prior to May 15, 2026, as well as Class 1 chemical drugs that have already obtained marketing authorization but remain eligible for data protection, a critically important transitional window applies:

• Applications Accepted but Pending Review Completion or Under Administrative Approval, or Already Approved (limited to eligible Class 1 chemical drugs): Eligible applicants must submit a data protection request to the CDE by June 5, 2026. Failure to submit within this timeframe will be treated as a definitive waiver of pharmaceutical trial data protection rights.

IV. Strategic takeaways

1. Leverage local manufacturing incentives

The Implementation Measures explicitly encourage foreign companies to transfer original drugs for domestic production in China. With the consent of the original drug holder, domestically produced drugs can seamlessly block generic applications that rely on the protected data. To leverage this benefit, and taking into account broader strategic, commercial, and regulatory considerations, multinational companies would consider initiating supply chain transfers to maximize data protection benefits within China, particularly given the potential to combine this mechanism with local patent enforcement strategies to create a more robust overall exclusivity position.

2. Accelerate global synchronized submissions

Given the 3-year protection mechanism granted to the first approved generic drug in China, multinational companies should reconsider the traditional "step-by-step" delayed marketing strategy in favor of global synchronized submissions. Accelerating simultaneous regulatory approval in China is essential to prevent domestic first generics from launching pre-emptively and establishing market positions that may prove difficult to displace. This consideration is particularly acute for biologics, where the first-to-file dynamic could significantly erode the commercial value of the originator product.

3. Re-evaluate pipeline valuation and licensing models

With the formal establishment of a comprehensive regulatory data protection regime, the exclusivity of multinational assets in China is now underpinned by a concrete, predictable administrative framework. Companies are strongly advised to re-evaluate financial models in licensing transactions and to design trigger clauses for royalty terms with precision (e.g., stipulating that royalty obligations expire on the later of patent expiration or regulatory exclusivity expiration). More broadly, the convergence of patent linkage and data exclusivity in China now offers a “dual-track” protection structure that, when strategically coordinated, can significantly extend the effective period of market exclusivity for innovative products.

Authored by Mingjia Deng, Zhen (Katie) Feng, Jessie Xie, and Stefaan Meuwissen.